Tracking Candida auris

On This Page

Candida auris is an emerging fungus that presents a serious global health threat. C. auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. auris for a long time and C. auris can persist on surfaces in healthcare environments. This can result in spread of C. auris between patients in healthcare facilities.

Strains of C. auris in the United States have been linked to other parts of the world. U.S. C. auris cases are a result of inadvertent introduction into the United States from a patient who recently received healthcare in a country where C. auris has been reported or a result of local spread after such an introduction.

Candida auris was made nationally notifiable at the 2018 Council for State and Territorial Epidemiologists (CSTE) Annual Conference. For the updated case definition and information on the nationally notifiable condition status, please see the 2018 CSTE position statement pdf icon[PDF – 16 pages]external icon.

To view the NNDSS HL7 Healthcare-Associated Infections, Multidrug-Resistant Organisms (HAI MDRO) Message Mapping Guide, which includes C. auris and CP-CRE, visit MMGs and Artifacts.

U.S. Map: Clinical cases of Candida auris reported by U.S. states, as of July 31, 2020
Graphic of Clinical cases of C. auris reported in the United States as of July 31, 2020

Cases are categorized by the state where the specimen was collected. Most probable cases were identified when laboratories with current cases of C. auris reviewed past microbiology records for C. auris. Isolates were not available for confirmation. Early detection of C. auris is essential for containing its spread in healthcare facilities.

Clinical cases of Candida auris reported by U.S. states, as of July 31, 2020

Clinical cases of Candida auris reported by state, United States

State Number and type of clinical Candida auris cases reported
Total
Confirmed Probable
Arizona 1 0
California 57 0
Connecticut 1 0
Florida 67 0
Georgia 2 0
Illinois 349 4
Indiana* 5 0
Maryland 11 0
Massachusetts 8 0
Minnesota 1 0
Mississippi 1 0
Nebraska 1 0
New Jersey 180 22
New York 574 4
North Carolina 1 0
Ohio 1 0
Oklahoma 2 0
Pennsylvania 2 0
Texas 6 0
Virginia 2 0
Washington DC* 0 0
TOTAL 1272 30

* Data may be out of date.

Beyond the clinical case counts reported above, an additional 2,493 patients have been found to be colonized with C. auris by targeted screening in 18 jurisdictions.

CDC will update case counts monthly.

CDC encourages all U.S. laboratories that identify C. auris to notify their state or local public health authorities and CDC at candidaauris@cdc.gov. CDC is working closely with public health and healthcare partners to prevent and respond to C. auris infections. The CDC-sponsored Antibiotic Resistance Laboratory Network (ARLN) will help improve detection and response to C. auris nationwide.

Countries from which Candida auris cases have been reported, as of July 31, 2020
Graphic with World Map C. Auris Tracking
  • Single cases of C. auris have been reported from Austria, Belgium, Chile, Costa Rica, Egypt, Greece, Italy, Iran, Norway, Poland, Switzerland, Taiwan, Thailand, and the United Arab Emirates.
  • Multiple cases of C. auris have been reported from Australia, Bangladesh, Canada, China, Colombia, France, Germany, India, Israel, Japan, Kenya, Kuwait, Malaysia, the Netherlands, Oman, Pakistan, Panama, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sudan, the United Kingdom, the United States, and Venezuela; in some of these countries, extensive transmission of C. auris has been documented in more than one hospital.
  • U.S. cases of C. auris have been found in patients who had recent stays in healthcare facilities in India, Kenya, Kuwait, Pakistan, South Africa, South Korea, the United Arab Emirates, and Venezuela, which also have documented cases.
  • Other countries not highlighted on this map may also have undetected or unreported C. auris cases.